Research programme: lipoic acid derivatives - Cornerstone Pharmaceuticals
Latest Information Update: 11 Apr 2011
At a glance
- Originator Cornerstone Pharmaceuticals
- Mechanism of Action Pyruvate dehydrogenase complex inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 11 Apr 2011 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 16 Apr 2008 Preclinical trials in Cancer in USA (unspecified route)